DIMA Biotech

DIMA Biotechnology Ltd. is a biotech company focusing on preclinical R&D products and services for druggable targets. They plan to complete the preparation of lead antibody molecules for all druggable targets in the next 3-5 years. DIMA Biotech provides multiple pre-prepared lead antibody molecules for each target to help pharmaceutical companies skip the tedious steps of monoclonal antibody platform establishment and lead molecule screening. Therefore, companies can have more time to focus on the biological mechanism and developability study of drug targets, thus accelerating the process of new drug R&D.

Over the years, DIMA Biotech has been deeply engaged in developing and optimizing the underlying technology platforms for preclinical research. Currently, they have established two independently developed core technology platforms:

Single/multiple transmembrane protein eukaryotic expression, preparation and purification platforms, apply mammalian cell expression systems, provide ECD or full-length membrane protein products closest to native conformation and functional validation. In addition, DIMA Biotech has developed five major functional full-length transmembrane protein preparation systems, including Membrane Nanoparticle (MNP), Virus-Like Particle (VLP), Exosome (EXO), Detergent and Synthetic Nanodisc. Thousands of drug target protein products are in stock.
DimAb® High-throughput single B-cell lead antibody molecule discovery platform. DIMA Biotech has completed the preparation and screening of lead antibody molecules against more than 200 drug targets by this platform in just two years. Moreover, they have formed strategic partnerships with several international pharmaceutical enterprises and licensed several drug target molecules. DIMA’s preclinical development strength is widely recognized by the industry.

www.dimabio.com

The prices are on request! Contact Us by e-mail info@sobekbio.com

Anti-CD19 antibody(DM207), Rabbit mAb DME100207

The add to cart button will appear once you select the values above

Specifications

size	10µg / 100µg / 500µg

Background:

Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.

Synonyms:

CD19,B4,CVID3,MGC12802

Clonality:

Monoclonal

Species reactivity:

Human

Host species:

Rabbit

Taraget:

CD19

Isotype:

Rabbit IgG

Purification:

Purified from cell culture supernatant by affinity chromatography

Applications:

ELISA|Flow Cyt

Recommended dilution:

ELISA 1/5000-10000;Flow Cyt 1/100

Formulation:

Liquid

Precaution:

Research use only

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com